Search

Your search keyword '"Gadkari, Deepak A."' showing total 20 results
Start Over Author "Gadkari, Deepak A."
20 results on '"Gadkari, Deepak A."'

1. Expansion of the measles and rubella laboratory network, India/Expansion du reseau de laboratoires d'analyse de la rougeole et de la rubeole en Inde/Ampliacion de la red de laboratorios para el diagnostico del sarampion y la rubeola en la India

Author

Sharma, Deepa, Sangal, Lucky, Vijay, Neetu, Nalavade, Uma, Krishnasamy, Kaveri, Pawar, Shailesh, Kaur, Harmanmeet, Narayan, Jitendra, Rane, Sneha, Narkar, Manish, Arumugam, Ramesh, Dhanagaran, D., Sugunan, A.P., Balakrishnan, Anukumar, Joseph, Bestin, Turuk, Jyotirmayee, Sabat, Jyotsnamayee, Sahoo, Prakash, Barde, Pradip, Sahare, Lalit, Ukey, Mahendra, Kumar, Manoj, Sinha, Nikesh, Bhuttoo, Zulfiquar Ali, Vijayachari, Paluru, Chander, Punnam, Sharma, Shivangi, Venkatesha, D., Gayathree, L., Sharma, Chethan, Bhatnagar, Pankaj, VanderEnde, Kristin, Kaundal, Nirmal, Murugan, Ratnesh, Haldar, Pradeep, Gadkari, Deepak, Aggarwal, Neeraj, and Gupta, Nivedita

Subjects
United States. Centers for Disease Control and Prevention -- Analysis, World Health Organization, Quality management, Analysis, Quality control, Measles -- Analysis, Quality control -- Analysis, Rubella -- Analysis, Health facilities construction -- Quality management
Abstract

Introduction Countries in the World Health Organization (WHO) South-East Asia Region have extended their targets to eliminate the vaccine-preventable infections, measles and rubella, by 2023. (1) These infections lead to [...], Objective To expand the measles and rubella laboratory network of India by integrating new laboratories. Methods In collaboration with the World Health Organization (WHO), the Indian government developed a 10-step scheme to systematically expand the number of laboratories performing serological and molecular testing for measles and rubella. The Indian Council of Medical Research and WHO identified suitable laboratories based on their geographical location, willingness, preparedness, past performance and adherence to national quality control and quality assurance mechanisms. The 10-step scheme was initiated with training on measles and rubella diagnostic assays followed by testing of both measles and rubella serology and molecular unknown panels, cross- verification with reference laboratories and ended with WHO on-site accreditation. Findings After extensive training, technical support, funding and monitoring, all six selected laboratories attained passing scores of 90.0% or more in serological and molecular proficiency testing of measles and rubella. Since 2018, the laboratories are a part of the measles and rubella network of India. Within 12 months of initiation of independent reporting, the six laboratories have tested 2287 serum samples and 701 throat or nasopharyngeal swabs or urine samples. Conclusion The process led to strengthening and expansion of the network. This proficient laboratory network has helped India in scaling up serological and molecular testing of measles and rubella while ensuring high quality testing. The collaborative model developed by the Indian government with WHO can be implemented by other countries for expanding laboratory networks for surveillance of measles and rubella as well as other infectious diseases. Objectif Etendre le reseau de laboratoires d'analyse de la rougeole et de la rubeole en Inde en y integrant de nouveaux etablissements. Methodes En collaboration avec l'Organisation mondiale de la Sante (OMS), le gouvernement indien a mis au point un programme en 10 etapes destine a accroitre systematiquement le nombre de laboratoires effectuant des tests serologiques et moleculaires de detection de la rougeole et de la rubeole. Le Conseil indien de la recherche medicale et l'OMS ont identifie une serie de laboratoires eligibles en raison de leur situation geographique, de leur volonte d'y participer, de leur niveau de preparation, de leurs performances anterieures et de leur respect des mecanismes nationaux de controle et d'assurance qualite. Ce programme en 10 etapes a commence par une formation aux analyses diagnostiques pour la rougeole et la rubeole, suivie de la realisation de tests serologiques et moleculaires pour detecter la rougeole et la rubeole sur des echantillons inconnus, une verification croisee avec les laboratoires de reference et enfin, une accreditation OMS sur site. Resultats Apres avoir recu une formation complete, un soutien technique, un financement et fait l'objet d'une surveillance, les six laboratoires selectionnes ont tous reussi, obtenant une note egale ou superieure a 90,0% dans les tests d'aptitude au depistage serologique et moleculaire de la rougeole et de la rubeole. Depuis 2018, ces laboratoires font partie du reseau d'analyse de la rougeole et de la rubeole en Inde. Douze mois apres l'etablissement des premiers rapports independants, les six laboratoires avaient teste 2287 echantillons de serum et 701 ecouvillons nasopharynges, prelevements de gorge ou echantillons d'urine. Conclusion Le programme a permis de renforcer et d'etendre le reseau de laboratoires competents. L'Inde a ainsi pu developper un systeme de tests serologiques et moleculaires de haute qualite pour depister la rougeole et la rubeole. Le modele collaboratif adopte par le gouvernement indien avec l'OMS pourrait s'appliquer a d'autres pays qui souhaitent etendre leur reseau de laboratoires charges de surveiller la rougeole et la rubeole, mais aussi d'autres maladies infectieuses. Objetivo Ampliar la red de laboratorios para el diagnostico del sarampion y la rubeola en la India mediante el establecimiento de nuevos laboratorios. Metodos En colaboracion con la Organizacion Mundial de la Salud (OMS), el gobierno de la India desarrollo un programa de 10 pasos para ampliar de manera sistematica el numero de laboratorios que realizan pruebas serologicas y moleculares para detectar el sarampion y la rubeola. El Consejo Indio de Investigacion Medica y la OMS identificaron los laboratorios adecuados segun su ubicacion geografica, su disposicion, su preparacion, sus resultados anteriores y su adhesion a los mecanismos nacionales de control y garantia de calidad. El programa de 10 pasos se inicio con la formacion sobre las pruebas de diagnostico del sarampion y la rubeola, seguida de la realizacion de pruebas serologicas y moleculares para el sarampion y la rubeola en grupos desconocidos, la verificacion cruzada con los laboratorios de referencia y finalizo con la acreditacion in situ a cargo de la OMS. Resultados Luego de una extensa formacion, apoyo tecnico, financiamiento y seguimiento, los seis laboratorios seleccionados alcanzaron puntajes de aprobacion del 90,0 % o mas en las pruebas de aptitud serologica y molecular para el sarampion y la rubeola. Desde 2018, los laboratorios forman parte de la red contra el sarampion y la rubeola de la India. En los 12 meses posteriores al inicio de la presentacion de informes independientes, los seis laboratorios han analizado 2287 muestras de suero y 701 exudados faringeos o nasofaringeos, o muestras de orina. Conclusion El proceso condujo al fortalecimiento y la expansion de la red. Esta competente red de laboratorios ha ayudado a India a ampliar las pruebas serologicas y moleculares para el sarampion y la rubeola, garantizando al mismo tiempo la alta calidad de las pruebas. El modelo de colaboracion que ha desarrollado el gobierno de la India con la OMS se puede aplicar en otros paises para ampliar las redes de laboratorios con el fin de vigilar los casos de sarampion y rubeola, asi como otras enfermedades infecciosas.

Published
2022
Full Text
View/download PDF

2. Global and regional epidemiology of HIV-1 recombinants in 1990–2015: a systematic review and global survey

Author

Abimiku, Alash'le G, Agwale, Simon, Archibald, Chris, Avidor, Boaz, Barbás, María Gabriela, Barre-Sinoussi, Francoise, Barugahare, Banson, Belabbes, El Hadj, Bertagnolio, Silvia, Birx, Deborah, Bobkov, Aleksei F, Brandful, James, Bredell, Helba, Brennan, Catherine A, Brooks, James, Bruckova, Marie, Buonaguro, Luigi, Buonaguro, Franco, Buttò, Stefano, Buvé, Anne, Campbell, Mary, Carr, Jean, Carrera, Alex, Carrillo, Manuel Gómez, Celum, Connie, Chaplin, Beth, Charles, Macarthur, Chatzidimitriou, Dimitrios, Chen, Zhiwei, Chijiwa, Katsumi, Cooper, David, Cunningham, Philip, Dagnra, Anoumou, de Gascun, Cillian F, Del Amo, Julia, Delgado, Elena, Dietrich, Ursula, Dwyer, Dominic, Ellenberger, Dennis, Ensoli, Barbara, Essex, Max, Gao, Feng, Fleury, Hervé, Fonjungo, Peter N, Foulongne, Vincent, Gadkari, Deepak A, García, Federico, Garsia, Roger, Gershy-Damet, Guy Michel, Glynn, Judith R, Goodall, Ruth, Grossman, Zehava, Lindenmeyer-Guimarães, Monick, Hahn, Beatrice, Hamers, Raph L, Hamouda, Osamah, Handema, Ray, He, Xiang, Herbeck, Joshua, Ho, David D, Holguin, Africa, Hosseinipour, Mina, Hunt, Gillian, Ito, Masahiko, Bel Hadj Kacem, Mohamed Ali, Kahle, Erin, Kaleebu, Pontiano, Kalish, Marcia, Kamarulzaman, Adeeba, Kang, Chun, Kanki, Phyllis, Karamov, Edward, Karasi, Jean-Claude, Kayitenkore, Kayitesi, Kelleher, Tony, Kitayaporn, Dwip, Kostrikis, Leondios G, Kucherer, Claudia, Lara, Claudia, Leitner, Thomas, Liitsola, Kirsi, Lingappa, Jai, Linka, Marek, Lorenzana de Rivera, Ivette, Lukashov, Vladimir, Maayan, Shlomo, Mayr, Luzia, McCutchan, Francine, Meda, Nicolas, Menu, Elisabeth, Mhalu, Fred, Mloka, Doreen, Mokili, John L, Montes, Brigitte, Mor, Orna, Morgado, Mariza, Mosha, Fausta, Moussi, Awatef, Mullins, James, Najera, Rafael, Nasr, Mejda, Ndembi, Nicaise, Neilson, Joel R, Nerurkar, Vivek R, Neuhann, Florian, Nolte, Claudine, Novitsky, Vlad, Nyambi, Philippe, Ofner, Marianna, Paladin, Fem J, Papa, Anna, Pape, Jean, Parkin, Neil, Parry, Chris, Peeters, Martine, Pelletier, Alexandra, Pérez-Álvarez, Lucía, Pillay, Deenan, Pinto, Angie, Quang, Trinh Duy, Rademeyer, Cecilia, Raikanikoda, Filimone, Rayfield, Mark A, Reynes, Jean-Marc, Rinke de Wit, Tobias, Robbins, Kenneth E, Rolland, Morgane, Rousseau, Christine, Salazar-Gonzales, Jesus, Salem, Hanan, Salminen, Mika, Salomon, Horacio, Sandstrom, Paul, Santiago, Mario L, Sarr, Abdoulaye D, Schroeder, Bryan, Segondy, Michel, Selhorst, Philippe, Sempala, Sylvester, Servais, Jean, Shaik, Ansari, Shao, Yiming, Slim, Amine, Soares, Marcelo A, Songok, Elijah, Stewart, Debbie, Stokes, Julie, Subbarao, Shambavi, Sutthent, Ruengpung, Takehisa, Jun, Tanuri, Amilcar, Tee, Kok Keng, Thapa, Kiran, Thomson, Michael, Tran, Tyna, Urassa, Willy, Ushijima, Hiroshi, van de Perre, Philippe, van der Groen, Guido, van Laethem, Kristel, van Oosterhout, Joep, van Sighem, Ard, van Wijngaerden, Eric, Vandamme, Anne-Mieke, Vercauteren, Jurgen, Vidal, Nicole, Wallace, Lesley, Williamson, Carolyn, Wolday, Dawit, Xu, Jianqing, Yang, Chunfu, Zhang, Linqi, Zhang, Rong, Hemelaar, Joris, Elangovan, Ramyiadarsini, Yun, Jason, Dickson-Tetteh, Leslie, Kirtley, Shona, Gouws-Williams, Eleanor, and Ghys, Peter D

Published
2020
Full Text
View/download PDF

4. Global and regional molecular epidemiology of HIV-1, 1990–2015: a systematic review, global survey, and trend analysis

Author

Abimiku, Alash'le G, Agwale, Simon, Archibald, Chris, Avidor, Boaz, Barbás, María Gabriela, Barre-Sinoussi, Francoise, Barugahare, Banson, Belabbes, El Hadj, Bertagnolio, Silvia, Birx, Deborah, Bobkov, Aleksei F, Brandful, James, Bredell, Helba, Brennan, Catherine A, Brooks, James, Bruckova, Marie, Buonaguro, Luigi, Buonaguro, Franco, Buttò, Stefano, Buve, Anne, Campbell, Mary, Carr, Jean, Carrera, Alex, Carrillo, Manuel Gómez, Celum, Connie, Chaplin, Beth, Charles, Macarthur, Chatzidimitriou, Dimitrios, Chen, Zhiwei, Chijiwa, Katsumi, Cooper, David, Cunningham, Philip, Dagnra, Anoumou, de Gascun, Cillian F, Del Amo, Julia, Delgado, Elena, Dietrich, Ursula, Dwyer, Dominic, Ellenberger, Dennis, Ensoli, Barbara, Essex, Max, Gao, Feng, Fleury, Herve, Fonjungo, Peter N, Foulongne, Vincent, Gadkari, Deepak A, García, Federico, Garsia, Roger, Gershy-Damet, Guy Michel, Glynn, Judith R, Goodall, Ruth, Grossman, Zehava, Lindenmeyer-Guimarães, Monick, Hahn, Beatrice, Hamers, Raph L, Hamouda, Osamah, Handema, Ray, He, Xiang, Herbeck, Joshua, Ho, David D, Holguin, Africa, Hosseinipour, Mina, Hunt, Gillian, Ito, Masahiko, Bel Hadj Kacem, Mohamed Ali, Kahle, Erin, Kaleebu, Pontiano Kaleebu, Kalish, Marcia, Kamarulzaman, Adeeba, Kang, Chun, Kanki, Phyllis, Karamov, Edward, Karasi, Jean-Claude, Kayitenkore, Kayitesi, Kelleher, Tony, Kitayaporn, Dwip, Kostrikis, Leondios G, Kucherer, Claudia, Lara, Claudia, Leitner, Thomas, Liitsola, Kirsi, Lingappa, Jai, Linka, Marek, Lorenzana de Rivera, Ivette, Lukashov, Vladimir, Maayan, Shlomo, Mayr, Luzia, McCutchan, Francine, Meda, Nicolas, Menu, Elisabeth, Mhalu, Fred, Mloka, Doreen, Mokili, John L, Montes, Brigitte, Mor, Orna, Morgado, Mariza, Mosha, Fausta, Moussi, Awatef, Mullins, James, Najera, Rafael, Nasr, Mejda, Ndembi, Nicaise, Neilson, Joel R, Nerurkar, Vivek R, Neuhann, Florian, Nolte, Claudine, Novitsky, Vlad, Nyambi, Philippe, Ofner, Marianna, Paladin, Fem J, Papa, Anna, Pape, Jean, Parkin, Neil, Parry, Chris, Peeters, Martine, Pelletier, Alexandra, Pérez-Álvarez, Lucía, Pillay, Deenan, Pinto, Angie, Quang, Trinh Duy, Rademeyer, Cecilia, Raikanikoda, Filimone, Rayfield, Mark A, Reynes, Jean-Marc, Rinke de Wit, Tobias, Robbins, Kenneth E, Rolland, Morgane, Rousseau, Christine, Salazar-Gonzales, Jesus, Salem, Hanan, Salminen, Mika, Salomon, Horacio, Sandstrom, Paul, Santiago, Mario L, Sarr, Abdoulaye D, Schroeder, Bryan, Segondy, Michel, Selhorst, Philippe, Sempala, Sylvester, Servais, Jean, Shaik, Ansari, Shao, Yiming, Slim, Amine, Soares, Marcelo A, Songok, Elijah, Stewart, Debbie, Stokes, Julie, Subbarao, Shambavi, Sutthent, Ruengpung, Takehisa, Jun, Tanuri, Amilcar, Tee, Kok Keng, Thapa, Kiran, Thomson, Michael, Tran, Tyna, Urassa, Willy, Ushijima, Hiroshi, van de Perre, Philippe, van der Groen, Guido, van Laethem, Kristel, van Oosterhout, Joep, van Sighem, Ard, van Wijngaerden, Eric, Vandamme, Anne-Mieke, Vercauteren, Jurgen, Vidal, Nicole, Wallace, Lesley, Williamson, Carolyn, Wolday, Dawit, Xu, Jianqing, Yang, Chunfu, Zhang, Linqi, Zhang, Rong, Hemelaar, Joris, Elangovan, Ramyiadarsini, Yun, Jason, Dickson-Tetteh, Leslie, Fleminger, Isabella, Kirtley, Shona, Williams, Brian, Gouws-Williams, Eleanor, and Ghys, Peter D

Published
2019
Full Text
View/download PDF

5. Expansion of the measles and rubella laboratory network, India

Author

Sharma, Deepa, Vijay, Neetu, Nalavade, Uma Prajwal, Krishnasamy, Kaveri, Pawar, Shailesh D., Kaur, Harmanmeet, Narayan, Jitendra, Rane, Sneha Vijay, Narkar, Manish, Arumugam, Ramesh, D, Dhanagaran, Bhatnagar, Pankaj, Ende, Kristin Vander, Kaundal, Nirmal, Murugan, Ratnesh, Haldar, Pradeep, Gadkari, Deepak, Aggarwal, Neeraj, Sangal, Lucky, Gupta, Nivedita, Sugunan, AP, Balakrishnan, Anukumar, Joseph, Bestin, Turuk, Jyotirmayee, Sabat, Jyotsnamayee, Sahoo, Prakash, Barde, Pradip, Sahare, Lalit, Ukey, Mahendra, Kumar, Manoj, Sinha, Nikesh, Bhuttoo, Zulfiquar Ali, Vijayachari, Paluru, Chander, Punnam, Sharma, Shivangi, Venkatesha, D, Gayathree, L, and Sharmam, Chethan

Subjects
Public Health, Environmental and Occupational Health, Humans, India, Global Health, Laboratories, Rubella, Measles
Abstract

To expand the measles and rubella laboratory network of India by integrating new laboratories.In collaboration with the World Health Organization (WHO), the Indian government developed a 10-step scheme to systematically expand the number of laboratories performing serological and molecular testing for measles and rubella. The Indian Council of Medical Research and WHO identified suitable laboratories based on their geographical location, willingness, preparedness, past performance and adherence to national quality control and quality assurance mechanisms. The 10-step scheme was initiated with training on measles and rubella diagnostic assays followed by testing of both measles and rubella serology and molecular unknown panels, cross-verification with reference laboratories and ended with WHO on-site accreditation.After extensive training, technical support, funding and monitoring, all six selected laboratories attained passing scores of 90.0% or more in serological and molecular proficiency testing of measles and rubella. Since 2018, the laboratories are a part of the measles and rubella network of India. Within 12 months of initiation of independent reporting, the six laboratories have tested 2287 serum samples and 701 throat or nasopharyngeal swabs or urine samples.The process led to strengthening and expansion of the network. This proficient laboratory network has helped India in scaling up serological and molecular testing of measles and rubella while ensuring high quality testing. The collaborative model developed by the Indian government with WHO can be implemented by other countries for expanding laboratory networks for surveillance of measles and rubella as well as other infectious diseases.Étendre le réseau de laboratoires d'analyse de la rougeole et de la rubéole en Inde en y intégrant de nouveaux établissements.En collaboration avec l'Organisation mondiale de la Santé (OMS), le gouvernement indien a mis au point un programme en 10 étapes destiné à accroître systématiquement le nombre de laboratoires effectuant des tests sérologiques et moléculaires de détection de la rougeole et de la rubéole. Le Conseil indien de la recherche médicale et l'OMS ont identifié une série de laboratoires éligibles en raison de leur situation géographique, de leur volonté d'y participer, de leur niveau de préparation, de leurs performances antérieures et de leur respect des mécanismes nationaux de contrôle et d'assurance qualité. Ce programme en 10 étapes a commencé par une formation aux analyses diagnostiques pour la rougeole et la rubéole, suivie de la réalisation de tests sérologiques et moléculaires pour détecter la rougeole et la rubéole sur des échantillons inconnus, une vérification croisée avec les laboratoires de référence et enfin, une accréditation OMS sur site.Après avoir reçu une formation complète, un soutien technique, un financement et fait l'objet d'une surveillance, les six laboratoires sélectionnés ont tous réussi, obtenant une note égale ou supérieure à 90,0% dans les tests d'aptitude au dépistage sérologique et moléculaire de la rougeole et de la rubéole. Depuis 2018, ces laboratoires font partie du réseau d'analyse de la rougeole et de la rubéole en Inde. Douze mois après l'établissement des premiers rapports indépendants, les six laboratoires avaient testé 2287 échantillons de sérum et 701 écouvillons nasopharyngés, prélèvements de gorge ou échantillons d'urine.Le programme a permis de renforcer et d'étendre le réseau de laboratoires compétents. L'Inde a ainsi pu développer un système de tests sérologiques et moléculaires de haute qualité pour dépister la rougeole et la rubéole. Le modèle collaboratif adopté par le gouvernement indien avec l'OMS pourrait s'appliquer à d'autres pays qui souhaitent étendre leur réseau de laboratoires chargés de surveiller la rougeole et la rubéole, mais aussi d'autres maladies infectieuses.Ampliar la red de laboratorios para el diagnóstico del sarampión y la rubéola en la India mediante el establecimiento de nuevos laboratorios.En colaboración con la Organización Mundial de la Salud (OMS), el gobierno de la India desarrolló un programa de 10 pasos para ampliar de manera sistemática el número de laboratorios que realizan pruebas serológicas y moleculares para detectar el sarampión y la rubéola. El Consejo Indio de Investigación Médica y la OMS identificaron los laboratorios adecuados según su ubicación geográfica, su disposición, su preparación, sus resultados anteriores y su adhesión a los mecanismos nacionales de control y garantía de calidad. El programa de 10 pasos se inició con la formación sobre las pruebas de diagnóstico del sarampión y la rubéola, seguida de la realización de pruebas serológicas y moleculares para el sarampión y la rubéola en grupos desconocidos, la verificación cruzada con los laboratorios de referencia y finalizó con la acreditaciónLuego de una extensa formación, apoyo técnico, financiamiento y seguimiento, los seis laboratorios seleccionados alcanzaron puntajes de aprobación del 90,0 % o más en las pruebas de aptitud serológica y molecular para el sarampión y la rubéola. Desde 2018, los laboratorios forman parte de la red contra el sarampión y la rubéola de la India. En los 12 meses posteriores al inicio de la presentación de informes independientes, los seis laboratorios han analizado 2287 muestras de suero y 701 exudados faríngeos o nasofaríngeos, o muestras de orina.El proceso condujo al fortalecimiento y la expansión de la red. Esta competente red de laboratorios ha ayudado a India a ampliar las pruebas serológicas y moleculares para el sarampión y la rubéola, garantizando al mismo tiempo la alta calidad de las pruebas. El modelo de colaboración que ha desarrollado el gobierno de la India con la OMS se puede aplicar en otros países para ampliar las redes de laboratorios con el fin de vigilar los casos de sarampión y rubéola, así como otras enfermedades infecciosas.توسيع شبكة مختبرات الحصبة والحصبة الألمانية في الهند من خلال دمج مختبرات جديدة.بالتعاون مع منظمة الصحة العالمية (WHO)، قامت الحكومة الهندية بتطوير مخطط يتألف من 10 خطوات بهدف زيادة عدد المختبرات التي تقوم بإجراء الاختبارات المصلية والجزيئية للحصبة والحصبة الألمانية، بشكل منهجي. حدد كل من المجلس الهندي للبحوث الطبية ومنظمة الصحة العالمية المختبرات المناسبة بناءً على موقعها الجغرافي، ورغبتها، واستعدادها، وأدائها السابق، والتزامها بالآليات الوطنية لمراقبة الجودة وتوكيد الجودة. تم بدء مخطط الخطوات العشر بالتدريب على الفحوصات التشخيصية للحصبة والحصبة الألمانية، وتبعها اختبار كل من مصل الحصبة والحصبة الألمانية والقوائم الجزيئية غير المعروفة، والتحقق المتبادل مع المختبرات المرجعية، وانتهى بالاعتماد الميداني لدى منظمة الصحة العالمية.بعد التدريب المكثف، والدعم الفني، والتمويل، والمراقبة، حققت كل المختبرات الستة المختارة على درجات اجتياز بلغت 90.0% أو أكثر، في اختبار الكفاءة المصلية والجزيئية للحصبة والحصبة الألمانية. منذ عام 2018، أصبحت المختبرات جزءًا من شبكة الحصبة والحصبة الألمانية في الهند. في غضون 12 شهرًا من بدء تقديم التقارير المستقلة، قامت المختبرات الستة باختبار 2287 عينة مصل و701 عينة من الحلق، أو البلعوم الأنفي، أو عينة بول.أدت تلك العملية إلى تعزيز وتوسيع الشبكة. ساعدت هذه الشبكة المتمكنة من المختبرات، الهند في توسيع نطاق الاختبارات المصلية والجزيئية للحصبة والحصبة الألمانية، مع ضمان إجراء اختبارات عالية الجودة. يمكن تنفيذ النموذج التعاوني الذي طورته الحكومة الهندية مع منظمة الصحة العالمية بواسطة دول أخرى لتوسيع شبكات المختبرات، من أجل مراقبة الحصبة والحصبة الألمانية فضلاً عن الأمراض المعدية الأخرى.旨在通过整合新的实验室，来扩大印度的麻疹和风疹实验室网络。.印度政府与世界卫生组织 (WHO) 合作制定了一个 10 步计划，以系统地扩大对麻疹和风疹进行血清学和分子检测的实验室的数量。印度医学研究委员会和世界卫生组织根据其地理位置、意愿、准备情况、过去的表现以及对国家质量控制和质量保证机制的遵守情况，确定了适当的实验室。该 10 步计划从麻疹和风疹诊断检测培训开始，随后测试麻疹和风疹血清学和未知分子小组，与参考实验室进行交叉验证，最后获得世卫组织现场认证。.经过广泛的培训、技术支持、资金支持和监测，所有六个选定的实验室在麻疹和风疹的血清学和分子水平测试中均获得了 90.0% 或更高的通过分数。自 2018 年以来，这些实验室成为印度麻疹和风疹网络的一部分。在独立报告开始后的 12 个月内，六个实验室已检测了 2287 份血清样本和 701 份咽喉或鼻咽拭子或尿液样本。.这个过程使得网络得到加强和扩展。这个熟练的实验室网络帮助印度扩大了麻疹和风疹的血清学和分子检测，同时确保了高质量的检测。印度政府与世卫组织开发的合作模式可以在其他国家实施，以扩大监测麻疹和风疹以及其他传染病的实验室网络。.Расширить сеть лабораторий для исследования кори и краснухи в Индии путем интеграции новых лабораторий.Правительство Индии в сотрудничестве со Всемирной организацией здравоохранения (ВОЗ) разработало 10-этапную схему систематического увеличения числа лабораторий, проводящих серологические и молекулярные тесты на корь и краснуху. Индийский совет по медицинским исследованиям и ВОЗ определили подходящие для этой цели лаборатории с учетом их географического положения, стремления участвовать, подготовленности, опыта работы и соблюдения национальных механизмов контроля и обеспечения качества. 10-этапная схема началась с обучения по проведению диагностических тестов на корь и краснуху, затем серологических тестов на корь и краснуху, а также с обучения использованию панелей молекулярной диагностики, продолжилась проведением перекрестной проверки с референс-лабораториями и завершилась аккредитацией ВОЗ на местах.После обширного обучения, технической поддержки, финансирования и мониторинга все шесть выбранных лабораторий получили проходные баллы 90,0% или выше при проведении квалификационных серологических и молекулярных тестов на корь и краснуху. С 2018 года лаборатории входят в сеть лабораторий Индии для исследования кори и краснухи. В течение 12 месяцев после начала независимой отчетности шесть лабораторий протестировали 2287 образцов сыворотки и 701 мазок из горла или носоглотки или образец мочи.Данный процесс привел к укреплению и расширению сети. Эта высокопрофессиональная лабораторная сеть помогла Индии расширить масштабы проведения серологических и молекулярных тестов на корь и краснуху, обеспечив при этом высокое качество тестирования. Модель сотрудничества, разработанная Правительством Индии и ВОЗ, может быть реализована другими странами в целях расширения сетей лабораторий для эпиднадзора за корью и краснухой, а также за другими инфекционными заболеваниями.

Published
2021

7. Low carotenoid concentration and the risk of HIV seroconversion in Pune, India

Author

Mehendale, Sanjay M., Shepherd, Mary E., Brookmeyer, Ronald S., Semba, Richard D., Divekar, Anand D., Gangakhedkar, Raman R., Joshi, Smita, Risbud, Arun R., Paranjape, Ramesh S., Gadkari, Deepak A., and Bollinger, Robert C.

Subjects
Vitamin A deficiency -- Health aspects, HIV infection in women -- Risk factors, Health
Abstract

Low blood levels of beta carotene and vitamin A may increase a woman's risk of HIV infection. This could occur because vitamin A deficiency produces changes in the vagina or because it affects the immune system.

Published
2001

8. Global and regional epidemiology of HIV-1 recombinants in 1990–2015: a systematic review and global survey

Author

Hemelaar, Joris, primary, Elangovan, Ramyiadarsini, additional, Yun, Jason, additional, Dickson-Tetteh, Leslie, additional, Kirtley, Shona, additional, Gouws-Williams, Eleanor, additional, Ghys, Peter D, additional, Abimiku, Alash'le G, additional, Agwale, Simon, additional, Archibald, Chris, additional, Avidor, Boaz, additional, Barbás, María Gabriela, additional, Barre-Sinoussi, Francoise, additional, Barugahare, Banson, additional, Belabbes, El Hadj, additional, Bertagnolio, Silvia, additional, Birx, Deborah, additional, Bobkov, Aleksei F, additional, Brandful, James, additional, Bredell, Helba, additional, Brennan, Catherine A, additional, Brooks, James, additional, Bruckova, Marie, additional, Buonaguro, Luigi, additional, Buonaguro, Franco, additional, Buttò, Stefano, additional, Buvé, Anne, additional, Campbell, Mary, additional, Carr, Jean, additional, Carrera, Alex, additional, Carrillo, Manuel Gómez, additional, Celum, Connie, additional, Chaplin, Beth, additional, Charles, Macarthur, additional, Chatzidimitriou, Dimitrios, additional, Chen, Zhiwei, additional, Chijiwa, Katsumi, additional, Cooper, David, additional, Cunningham, Philip, additional, Dagnra, Anoumou, additional, de Gascun, Cillian F, additional, Del Amo, Julia, additional, Delgado, Elena, additional, Dietrich, Ursula, additional, Dwyer, Dominic, additional, Ellenberger, Dennis, additional, Ensoli, Barbara, additional, Essex, Max, additional, Gao, Feng, additional, Fleury, Hervé, additional, Fonjungo, Peter N, additional, Foulongne, Vincent, additional, Gadkari, Deepak A, additional, García, Federico, additional, Garsia, Roger, additional, Gershy-Damet, Guy Michel, additional, Glynn, Judith R, additional, Goodall, Ruth, additional, Grossman, Zehava, additional, Lindenmeyer-Guimarães, Monick, additional, Hahn, Beatrice, additional, Hamers, Raph L, additional, Hamouda, Osamah, additional, Handema, Ray, additional, He, Xiang, additional, Herbeck, Joshua, additional, Ho, David D, additional, Holguin, Africa, additional, Hosseinipour, Mina, additional, Hunt, Gillian, additional, Ito, Masahiko, additional, Bel Hadj Kacem, Mohamed Ali, additional, Kahle, Erin, additional, Kaleebu, Pontiano, additional, Kalish, Marcia, additional, Kamarulzaman, Adeeba, additional, Kang, Chun, additional, Kanki, Phyllis, additional, Karamov, Edward, additional, Karasi, Jean-Claude, additional, Kayitenkore, Kayitesi, additional, Kelleher, Tony, additional, Kitayaporn, Dwip, additional, Kostrikis, Leondios G, additional, Kucherer, Claudia, additional, Lara, Claudia, additional, Leitner, Thomas, additional, Liitsola, Kirsi, additional, Lingappa, Jai, additional, Linka, Marek, additional, Lorenzana de Rivera, Ivette, additional, Lukashov, Vladimir, additional, Maayan, Shlomo, additional, Mayr, Luzia, additional, McCutchan, Francine, additional, Meda, Nicolas, additional, Menu, Elisabeth, additional, Mhalu, Fred, additional, Mloka, Doreen, additional, Mokili, John L, additional, Montes, Brigitte, additional, Mor, Orna, additional, Morgado, Mariza, additional, Mosha, Fausta, additional, Moussi, Awatef, additional, Mullins, James, additional, Najera, Rafael, additional, Nasr, Mejda, additional, Ndembi, Nicaise, additional, Neilson, Joel R, additional, Nerurkar, Vivek R, additional, Neuhann, Florian, additional, Nolte, Claudine, additional, Novitsky, Vlad, additional, Nyambi, Philippe, additional, Ofner, Marianna, additional, Paladin, Fem J, additional, Papa, Anna, additional, Pape, Jean, additional, Parkin, Neil, additional, Parry, Chris, additional, Peeters, Martine, additional, Pelletier, Alexandra, additional, Pérez-Álvarez, Lucía, additional, Pillay, Deenan, additional, Pinto, Angie, additional, Quang, Trinh Duy, additional, Rademeyer, Cecilia, additional, Raikanikoda, Filimone, additional, Rayfield, Mark A, additional, Reynes, Jean-Marc, additional, Rinke de Wit, Tobias, additional, Robbins, Kenneth E, additional, Rolland, Morgane, additional, Rousseau, Christine, additional, Salazar-Gonzales, Jesus, additional, Salem, Hanan, additional, Salminen, Mika, additional, Salomon, Horacio, additional, Sandstrom, Paul, additional, Santiago, Mario L, additional, Sarr, Abdoulaye D, additional, Schroeder, Bryan, additional, Segondy, Michel, additional, Selhorst, Philippe, additional, Sempala, Sylvester, additional, Servais, Jean, additional, Shaik, Ansari, additional, Shao, Yiming, additional, Slim, Amine, additional, Soares, Marcelo A, additional, Songok, Elijah, additional, Stewart, Debbie, additional, Stokes, Julie, additional, Subbarao, Shambavi, additional, Sutthent, Ruengpung, additional, Takehisa, Jun, additional, Tanuri, Amilcar, additional, Tee, Kok Keng, additional, Thapa, Kiran, additional, Thomson, Michael, additional, Tran, Tyna, additional, Urassa, Willy, additional, Ushijima, Hiroshi, additional, van de Perre, Philippe, additional, van der Groen, Guido, additional, van Laethem, Kristel, additional, van Oosterhout, Joep, additional, van Sighem, Ard, additional, van Wijngaerden, Eric, additional, Vandamme, Anne-Mieke, additional, Vercauteren, Jurgen, additional, Vidal, Nicole, additional, Wallace, Lesley, additional, Williamson, Carolyn, additional, Wolday, Dawit, additional, Xu, Jianqing, additional, Yang, Chunfu, additional, Zhang, Linqi, additional, and Zhang, Rong, additional

Published
2020
Full Text
View/download PDF

9. Risk factors and clinical presentation of acute primary HIV infection in India

Author

Bollinger, Robert C., Brookmeyer, Ronald S., Mehendale, Sanjay M., Paranjape, Ramesh S., Shepherd, Mary E., Gadkari, Deepak A., and Quinn, Thomas C.

Subjects
Viral antigens -- Measurement, HIV testing -- Innovations, HIV infection -- Diagnosis
Abstract

Testing blood samples for the HIV p24 antigen may help detect HIV infection earlier. This viral protein is produced when the virus is actively reproducing and may occur sooner than the antibodies that most HIV tests rely on. Researchers tested blood samples from 3,874 people who tested negative for HIV antibodies for the p24 antigen. Fifty-eight tested positive. Unprotected sex with prostitutes and genital ulcers were risk factors for HIV infection. Fever, joint pain and night sweats were more common in p24-positive persons, occurring in almost half. These could be signs of early HIV infection., Context.--Most previous studies of clinical presentation and risk factors in early human immunodeficiency virus (HIV) infection have relied on retrospective analyses and referred seroconverters, and thus were subject to possible bias. Objectives.--To apply a method based on measurement of prevalent HIV-1 p24 antigenemia for identification of risk factors for newly acquired HiV infection and to describe the signs and symptoms of acute HIV infection. Design and Setting.--Nested case-control study in Pune, India. Participants.--HIV antibody-negative persons attending 2 sexually transmitted disease (STD) clinics between May 1993 and June 1996. Outcome Measures.--Prevalent p24 antigenemia, risk factors for HIV infection, and clinical symptoms of acute primary HIV infection. Results.--Of 3874 HIV antibody-negative persons tested, 58 (1.5%) were p24 antigen positive at initial presentation to the clinics. Unprotected sexual contact with a commercial sex worker (CSW) was reported by 39 (77%) of the 51 p24 antigenemic men, compared with 131 (51%) of 255 control men (adjusted odds ratio [AOR], 3.4; 95% confidence interval [CI], 1.2-9.6; P=.02). The presence of an active genital ulcer at the time of screening was found in 46 (79%) of the 58 p24 antigenemic men and women, compared with 137 (47%) of the 290 control subjects (AOR, 4.2; 95% CI, 2.0-9.0; P[is less than] .001). Signs and symptoms independently associated with p24 antigenemia in HIV antibody-seronegative persons included fever, which was reported by 28 (48%) of the 58 p24 antigenemic subjects, but only 52 (18%) of the 290 control subjects (AOR, 4.7; 95% CI, 2.4-9.0; P [is less than] .001). Joint pain was reported by 10% of subjects recently HIV infected, compared with 2% of the control subjects (AOR, 6.5; 95% CI, 1.7-24.8; P=.006). Night sweats were reported by 9% of the p24 antigenemic, but only 1% of the control subjects (AOR, 9.1; 95% CI, 1.7-47.6; P = .009). Overall, fever, joint pain, and/or night sweats were reported in 27 (47%) of the 58 subjects with recent HIV infection. Conclusions.--This systematic case-control study of p24 antigen screening in HIV-seronegative patients attending STD clinics in India identified unprotected sex with a CSW and a genital ulcer as independent. risk factors associated with newly acquired HIV infection. In addition, p24 antigen positivity identified recent fever, night sweats, and arthralgias as symptoms that may be predictive of recent HIV infection. In a study of patients attending STD clinics in India, screening for p24 antigen in HIV antibody-negative persons was found to be a reliable and effective research method for determining recent risk behavior and identifying clinical signs of acute primary HIV infection. JAMA. 1997;278:2085-2089

Published
1997

11. Global and regional molecular epidemiology of HIV-1, 1990–2015: a systematic review, global survey, and trend analysis

Author

Hemelaar, Joris, Elangovan, Ramyiadarsini, Yun, Jason, Dickson-Tetteh, Leslie, Fleminger, Isabella, Kirtley, Shona, Williams, Brian, Gouws-Williams, Eleanor, Ghys, Peter D, Abimiku, Alash'le G, Agwale, Simon, Archibald, Chris, Avidor, Boaz, Barbás, María Gabriela, Barre-Sinoussi, Francoise, Barugahare, Banson, Belabbes, El Hadj, Bertagnolio, Silvia, Birx, Deborah, Bobkov, Aleksei F, Brandful, James, Bredell, Helba, Brennan, Catherine A, Brooks, James, Bruckova, Marie, Buonaguro, Luigi, Buonaguro, Franco, Buttò, Stefano, Buve, Anne, Campbell, Mary, Carr, Jean, Carrera, Alex, Carrillo, Manuel Gómez, Celum, Connie, Chaplin, Beth, Charles, Macarthur, Chatzidimitriou, Dimitrios, Chen, Zhiwei, Chijiwa, Katsumi, Cooper, David, Cunningham, Philip, Dagnra, Anoumou, de Gascun, Cillian F, Del Amo, Julia, Delgado, Elena, Dietrich, Ursula, Dwyer, Dominic, Ellenberger, Dennis, Ensoli, Barbara, Essex, Max, Gao, Feng, Fleury, Herve, Fonjungo, Peter N, Foulongne, Vincent, Gadkari, Deepak A, García, Federico, Garsia, Roger, Gershy-Damet, Guy Michel, Glynn, Judith R, Goodall, Ruth, Grossman, Zehava, Lindenmeyer-Guimarães, Monick, Hahn, Beatrice, Hamers, Raph L, Hamouda, Osamah, Handema, Ray, He, Xiang, Herbeck, Joshua, Ho, David D, Holguin, Africa, Hosseinipour, Mina, Hunt, Gillian, Ito, Masahiko, Bel Hadj Kacem, Mohamed Ali, Kahle, Erin, Kaleebu, Pontiano Kaleebu, Kalish, Marcia, Kamarulzaman, Adeeba, Kang, Chun, Kanki, Phyllis, Karamov, Edward, Karasi, Jean-Claude, Kayitenkore, Kayitesi, Kelleher, Tony, Kitayaporn, Dwip, Kostrikis, Leondios G, Kucherer, Claudia, Lara, Claudia, Leitner, Thomas, Liitsola, Kirsi, Lingappa, Jai, Linka, Marek, Lorenzana de Rivera, Ivette, Lukashov, Vladimir, Maayan, Shlomo, Mayr, Luzia, McCutchan, Francine, Meda, Nicolas, Menu, Elisabeth, Mhalu, Fred, Mloka, Doreen, Mokili, John L, Montes, Brigitte, Mor, Orna, Morgado, Mariza, Mosha, Fausta, Moussi, Awatef, Mullins, James, Najera, Rafael, Nasr, Mejda, Ndembi, Nicaise, Neilson, Joel R, Nerurkar, Vivek R, Neuhann, Florian, Nolte, Claudine, Novitsky, Vlad, Nyambi, Philippe, Ofner, Marianna, Paladin, Fem J, Papa, Anna, Pape, Jean, Parkin, Neil, Parry, Chris, Peeters, Martine, Pelletier, Alexandra, Pérez-Álvarez, Lucía, Pillay, Deenan, Pinto, Angie, Quang, Trinh Duy, Rademeyer, Cecilia, Raikanikoda, Filimone, Rayfield, Mark A, Reynes, Jean-Marc, Rinke de Wit, Tobias, Robbins, Kenneth E, Rolland, Morgane, Rousseau, Christine, Salazar-Gonzales, Jesus, Salem, Hanan, Salminen, Mika, Salomon, Horacio, Sandstrom, Paul, Santiago, Mario L, Sarr, Abdoulaye D, Schroeder, Bryan, Segondy, Michel, Selhorst, Philippe, Sempala, Sylvester, Servais, Jean, Shaik, Ansari, Shao, Yiming, Slim, Amine, Soares, Marcelo A, Songok, Elijah, Stewart, Debbie, Stokes, Julie, Subbarao, Shambavi, Sutthent, Ruengpung, Takehisa, Jun, Tanuri, Amilcar, Tee, Kok Keng, Thapa, Kiran, Thomson, Michael, Tran, Tyna, Urassa, Willy, Ushijima, Hiroshi, van de Perre, Philippe, van der Groen, Guido, van Laethem, Kristel, van Oosterhout, Joep, van Sighem, Ard, van Wijngaerden, Eric, Vandamme, Anne-Mieke, Vercauteren, Jurgen, Vidal, Nicole, Wallace, Lesley, Williamson, Carolyn, Wolday, Dawit, Xu, Jianqing, Yang, Chunfu, Zhang, Linqi, Zhang, Rong, John Radcliffe Hospital [Oxford University Hospital], Centre for Statistics in Medicine, University of Oxford [Oxford], Stellenbosch University, UNAIDS [Genève, Suisse] (ONUSIDA), Institut Pasteur [Paris], Noguchi Memorial Institute for Medical Research [Accra, Ghana] (NMIMR), University of Ghana, Institute of Tropical Medicine [Antwerp] (ITM), State Key Laboratory of Silkworm Genome Biology, Southwest University, Commissariat à l'énergie atomique et aux énergies alternatives - Laboratoire d'Electronique et de Technologie de l'Information (CEA-LETI), Direction de Recherche Technologique (CEA) (DRT (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Georg-Speyer-Haus, The University of Sydney, National AIDS Centre, Istituto Superiore di Sanita [Rome], Harvard School of Public Health, Digital Enterprise Research Institute (DERI-NUIG), National University of Ireland [Galway] (NUI Galway), Microbiologie cellulaire et moléculaire et pathogénicité (MCMP), Université Bordeaux Segalen - Bordeaux 2-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Virologie, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Pathogénèse et contrôle des infections chroniques (PCCI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Departments of Medicine and Microbiology, University of Alabama at Birmingham [ Birmingham] (UAB), Robert Koch Institute [Berlin] (RKI), Beihang University (BUAA), Statens Serum Institut [Copenhagen], Immuno-Rhumatologie Moléculaire, Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), SANTE/SIDA [Bobo-Dioulasso, Burkina Faso], Institut de Recherche en Sciences de la Santé (IRSS) / Centre Muraz, Department of Microbiology, University of Washington School of Medicine, Department of Microbiology, Medical School, University of Thessaly [Volos] (UTH), Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques er émergentes (TransVIHMI), Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Université Montpellier 1 (UM1), Africa Centre for Health and Population Studies, University of KwaZulu-Natal (UKZN)-Medical Research Council of South Africa, Lab-STICC_UBO_CID_IHSEV, Laboratoire des sciences et techniques de l'information, de la communication et de la connaissance (Lab-STICC), École Nationale d'Ingénieurs de Brest (ENIB)-Université de Bretagne Sud (UBS)-Université de Brest (UBO)-Télécom Bretagne-Institut Brestois du Numérique et des Mathématiques (IBNM), Université de Brest (UBO)-Université européenne de Bretagne - European University of Brittany (UEB)-École Nationale Supérieure de Techniques Avancées Bretagne (ENSTA Bretagne)-Institut Mines-Télécom [Paris] (IMT)-Centre National de la Recherche Scientifique (CNRS)-École Nationale d'Ingénieurs de Brest (ENIB)-Université de Bretagne Sud (UBS)-Université de Brest (UBO)-Télécom Bretagne-Institut Brestois du Numérique et des Mathématiques (IBNM), Université de Brest (UBO)-Université européenne de Bretagne - European University of Brittany (UEB)-École Nationale Supérieure de Techniques Avancées Bretagne (ENSTA Bretagne)-Institut Mines-Télécom [Paris] (IMT)-Centre National de la Recherche Scientifique (CNRS), State Key Laboratory of Infectious Disease Prevention and Control, Chinese Center for Disease Control and Prevention, Laboratory of Virology, CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Universidade Federal do Rio de Janeiro (UFRJ), Departements of Medicine and Microbiology, University of Alabama [Tuscaloosa] (UA), Stichting HIV Monitoring [Amsterdam], Universiteit van Amsterdam (UvA), Département Génétique Internal Médecine, Hôpital Universitaire Leuven, Department of Chemical and Biomolecular Engineering [Baltimore], Johns Hopkins University (JHU), Centers for Disease Control and Prevention [Atlanta] (CDC), Centers for Disease Control and Prevention, China Academy of Chinese Medical Sciences, Chatzidimitriou, Dimitrios [0000-0001-9656-5898], University of Oxford, Institut Pasteur [Paris] (IP), Istituto Superiore di Sanità (ISS), Microbiologie Fondamentale et Pathogénicité (MFP), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques et émergentes (TransVIHMI), Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), University of KwaZulu-Natal [Durban, Afrique du Sud] (UKZN)-Medical Research Council of South Africa, Université européenne de Bretagne - European University of Brittany (UEB)-École Nationale d'Ingénieurs de Brest (ENIB)-Université de Bretagne Sud (UBS)-Université de Brest (UBO)-Télécom Bretagne-Institut Brestois du Numérique et des Mathématiques (IBNM), Université de Brest (UBO)-École Nationale Supérieure de Techniques Avancées Bretagne (ENSTA Bretagne)-Institut Mines-Télécom [Paris] (IMT)-Centre National de la Recherche Scientifique (CNRS)-Université européenne de Bretagne - European University of Brittany (UEB)-École Nationale d'Ingénieurs de Brest (ENIB)-Université de Bretagne Sud (UBS)-Université de Brest (UBO)-Télécom Bretagne-Institut Brestois du Numérique et des Mathématiques (IBNM), Université de Brest (UBO)-École Nationale Supérieure de Techniques Avancées Bretagne (ENSTA Bretagne)-Institut Mines-Télécom [Paris] (IMT)-Centre National de la Recherche Scientifique (CNRS), UNAIDS, Noguchi Memorial Institute for Medical Research, University of Ghana, Laboratoire d'Electronique et des Technologies de l'Information (CEA-LETI), Université Grenoble Alpes (UGA)-Direction de Recherche Technologique (CEA) (DRT (CEA)), Beihang University, Recherches Translationnelles sur le VIH et les maladies infectieuses (TransVIHMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Recherche pour le Développement (IRD)-Université Montpellier 1 (UM1)-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Universtié Yaoundé 1 [Cameroun]-Université de Montpellier (UM), Universidade Federal do Rio de Janeiro [Rio de Janeiro] (UFRJ), Nuffield Department of Women's and Reproductive Health (NDWRH), University of Oxford- John Radcliffe Hospital [Oxford University Hospital], South African Centre for Epidemiological Modelling and Analysis, JH is supported by the Oxford University Clinical Academic Graduate School (Oxford, UK) and Linacre College, Oxford University (Oxford, UK)., WHO–UNAIDS Network for HIV Isolation Characterisation : Alash'le G Abimiku, Simon Agwale, Chris Archibald, Boaz Avidor, María Gabriela Barbás, Francoise Barre-Sinoussi, Banson Barugahare, El Hadj Belabbes, Silvia Bertagnolio, Deborah Birx, Aleksei F Bobkov, James Brandful, Helba Bredell, Catherine A Brennan, James Brooks, Marie Bruckova, Luigi Buonaguro, Franco Buonaguro, Stefano Buttò, Anne Buve, Mary Campbell, Jean Carr, Alex Carrera, Manuel Gómez Carrillo, Connie Celum, Beth Chaplin, Macarthur Charles, Dimitrios Chatzidimitriou, Zhiwei Chen, Katsumi Chijiwa, David Cooper, Philip Cunningham, Anoumou Dagnra, Cillian F de Gascun, Julia Del Amo, Elena Delgado, Ursula Dietrich, Dominic Dwyer, Dennis Ellenberger, Barbara Ensoli, Max Essex, Feng Gao, Herve Fleury, Peter N Fonjungo, Vincent Foulongne, Deepak A Gadkari, Federico García, Roger Garsia, Guy Michel Gershy-Damet, Judith R Glynn, Ruth Goodall, Zehava Grossman, Monick Lindenmeyer-Guimarães, Beatrice Hahn, Raph L Hamers, Osamah Hamouda, Ray Handema, Xiang He, Joshua Herbeck, David D Ho, Africa Holguin, Mina Hosseinipour, Gillian Hunt, Masahiko Ito, Mohamed Ali Bel Hadj Kacem, Erin Kahle, Pontiano Kaleebu Kaleebu, Marcia Kalish, Adeeba Kamarulzaman, Chun Kang, Phyllis Kanki, Edward Karamov, Jean-Claude Karasi, Kayitesi Kayitenkore, Tony Kelleher, Dwip Kitayaporn, Leondios G Kostrikis, Claudia Kucherer, Claudia Lara, Thomas Leitner, Kirsi Liitsola, Jai Lingappa, Marek Linka, Ivette Lorenzana de Rivera, Vladimir Lukashov, Shlomo Maayan, Luzia Mayr, Francine McCutchan, Nicolas Meda, Elisabeth Menu, Fred Mhalu, Doreen Mloka, John L Mokili, Brigitte Montes, Orna Mor, Mariza Morgado, Fausta Mosha, Awatef Moussi, James Mullins, Rafael Najera, Mejda Nasr, Nicaise Ndembi, Joel R Neilson, Vivek R Nerurkar, Florian Neuhann, Claudine Nolte, Vlad Novitsky, Philippe Nyambi, Marianna Ofner, Fem J Paladin, Anna Papa, Jean Pape, Neil Parkin, Chris Parry, Martine Peeters, Alexandra Pelletier, Lucía Pérez-Álvarez, Deenan Pillay, Angie Pinto, Trinh Duy Quang, Cecilia Rademeyer, Filimone Raikanikoda, Mark A Rayfield, Jean-Marc Reynes, Tobias Rinke de Wit, Kenneth E Robbins, Morgane Rolland, Christine Rousseau, Jesus Salazar-Gonzales, Hanan Salem, Mika Salminen, Horacio Salomon, Paul Sandstrom, Mario L Santiago, Abdoulaye D Sarr, Bryan Schroeder, Michel Segondy, Philippe Selhorst, Sylvester Sempala, Jean Servais, Ansari Shaik, Yiming Shao, Amine Slim, Marcelo A Soares, Elijah Songok, Debbie Stewart, Julie Stokes, Shambavi Subbarao, Ruengpung Sutthent, Jun Takehisa, Amilcar Tanuri, Kok Keng Tee, Kiran Thapa, Michael Thomson, Tyna Tran, Willy Urassa, Hiroshi Ushijima, Philippevan de Perre, Guidovan der Groen, Kristel van Laethem, Joep van Oosterhout, Ard van Sighem, Eric van Wijngaerden, Anne-Mieke Vandamme, Jurgen Vercauteren, Nicole Vidal, Lesley Wallace, Carolyn Williamson, Dawit Wolday, Jianqing Xu, Chunfu Yang, Linqi Zhang, and Rong Zhang

Subjects
0301 basic medicine, Serotype, Genotype, Genotyping Techniques, 030106 microbiology, DIVERSITY, MULTICENTER, VACCINE, HIV Infections, Genome, Viral, Biology, Global Health, Serogroup, SUBTYPES, 03 medical and health sciences, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Surveys and Questionnaires, INFECTION, Genetic variation, Global health, Humans, HIV vaccine, Serotyping, AIDS Vaccines, Science & Technology, Molecular epidemiology, Genetic Variation, Subtyping, 3. Good health, Trend analysis, 030104 developmental biology, Infectious Diseases, 13. Climate action, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, HIV-1, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Life Sciences & Biomedicine, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Demography
Abstract

BACKGROUND: Global genetic diversity of HIV-1 is a major challenge to the development of HIV vaccines. We aimed to estimate the regional and global distribution of HIV-1 subtypes and recombinants during 1990-2015. METHODS: We searched PubMed, EMBASE (Ovid), CINAHL (Ebscohost), and Global Health (Ovid) for HIV-1 subtyping studies published between Jan 1, 1990, and Dec 31, 2015. We collected additional unpublished HIV-1 subtyping data through a global survey. We included prevalence studies with HIV-1 subtyping data collected during 1990-2015. We grouped countries into 14 regions and analysed data for four time periods (1990-99, 2000-04, 2005-09, and 2010-15). The distribution of HIV-1 subtypes, circulating recombinant forms (CRFs), and unique recombinant forms (URFs) in individual countries was weighted according to the UNAIDS estimates of the number of people living with HIV (PLHIV) in each country to generate regional and global estimates of HIV-1 diversity in each time period. The primary outcome was the number of samples designated as HIV-1 subtypes A, B, C, D, F, G, H, J, K, CRFs, and URFs. The systematic review is registered with PROSPERO, number CRD42017067164. FINDINGS: This systematic review and global survey yielded 2203 datasets with 383 519 samples from 116 countries in 1990-2015. Globally, subtype C accounted for 46·6% (16 280 897/34 921 639 of PLHIV) of all HIV-1 infections in 2010-15. Subtype B was responsible for 12·1% (4 235 299/34 921 639) of infections, followed by subtype A (10·3%; 3 587 003/34 921 639), CRF02_AG (7·7%; 2 705 110/34 921 639), CRF01_AE (5·3%; 1 840 982/34 921 639), subtype G (4·6%; 1 591 276/34 921 639), and subtype D (2·7%; 926 255/34 921 639). Subtypes F, H, J, and K combined accounted for 0·9% (311 332/34 921 639) of infections. Other CRFs accounted for 3·7% (1 309 082/34 921 639), bringing the proportion of all CRFs to 16·7% (5 844 113/34 921 639). URFs constituted 6·1% (2 134 405/34 921 639), resulting in recombinants accounting for 22·8% (7 978 517/34 921 639) of all global HIV-1 infections. The distribution of HIV-1 subtypes and recombinants changed over time in countries, regions, and globally. At a global level during 2005-15, subtype B increased, subtypes A and D were stable, and subtypes C and G and CRF02_AG decreased. CRF01_AE, other CRFs, and URFs increased, leading to a consistent increase in the global proportion of recombinants over time. INTERPRETATION: Global and regional HIV diversity is complex and evolving, and is a major challenge to HIV vaccine development. Surveillance of the global molecular epidemiology of HIV-1 remains crucial for the design, testing, and implementation of HIV vaccines. FUNDING: None. ispartof: LANCET INFECTIOUS DISEASES vol:19 issue:2 pages:143-155 ispartof: location:United States status: published

Published
2018
Full Text
View/download PDF

14. Global and regional molecular epidemiology of HIV-1, 1990–2015: a systematic review, global survey, and trend analysis

Author

Hemelaar, Joris, primary, Elangovan, Ramyiadarsini, additional, Yun, Jason, additional, Dickson-Tetteh, Leslie, additional, Fleminger, Isabella, additional, Kirtley, Shona, additional, Williams, Brian, additional, Gouws-Williams, Eleanor, additional, Ghys, Peter D, additional, Abimiku, Alash'le G, additional, Agwale, Simon, additional, Archibald, Chris, additional, Avidor, Boaz, additional, Barbás, María Gabriela, additional, Barre-Sinoussi, Francoise, additional, Barugahare, Banson, additional, Belabbes, El Hadj, additional, Bertagnolio, Silvia, additional, Birx, Deborah, additional, Bobkov, Aleksei F, additional, Brandful, James, additional, Bredell, Helba, additional, Brennan, Catherine A, additional, Brooks, James, additional, Bruckova, Marie, additional, Buonaguro, Luigi, additional, Buonaguro, Franco, additional, Buttò, Stefano, additional, Buve, Anne, additional, Campbell, Mary, additional, Carr, Jean, additional, Carrera, Alex, additional, Carrillo, Manuel Gómez, additional, Celum, Connie, additional, Chaplin, Beth, additional, Charles, Macarthur, additional, Chatzidimitriou, Dimitrios, additional, Chen, Zhiwei, additional, Chijiwa, Katsumi, additional, Cooper, David, additional, Cunningham, Philip, additional, Dagnra, Anoumou, additional, de Gascun, Cillian F, additional, Del Amo, Julia, additional, Delgado, Elena, additional, Dietrich, Ursula, additional, Dwyer, Dominic, additional, Ellenberger, Dennis, additional, Ensoli, Barbara, additional, Essex, Max, additional, Gao, Feng, additional, Fleury, Herve, additional, Fonjungo, Peter N, additional, Foulongne, Vincent, additional, Gadkari, Deepak A, additional, García, Federico, additional, Garsia, Roger, additional, Gershy-Damet, Guy Michel, additional, Glynn, Judith R, additional, Goodall, Ruth, additional, Grossman, Zehava, additional, Lindenmeyer-Guimarães, Monick, additional, Hahn, Beatrice, additional, Hamers, Raph L, additional, Hamouda, Osamah, additional, Handema, Ray, additional, He, Xiang, additional, Herbeck, Joshua, additional, Ho, David D, additional, Holguin, Africa, additional, Hosseinipour, Mina, additional, Hunt, Gillian, additional, Ito, Masahiko, additional, Bel Hadj Kacem, Mohamed Ali, additional, Kahle, Erin, additional, Kaleebu, Pontiano Kaleebu, additional, Kalish, Marcia, additional, Kamarulzaman, Adeeba, additional, Kang, Chun, additional, Kanki, Phyllis, additional, Karamov, Edward, additional, Karasi, Jean-Claude, additional, Kayitenkore, Kayitesi, additional, Kelleher, Tony, additional, Kitayaporn, Dwip, additional, Kostrikis, Leondios G, additional, Kucherer, Claudia, additional, Lara, Claudia, additional, Leitner, Thomas, additional, Liitsola, Kirsi, additional, Lingappa, Jai, additional, Linka, Marek, additional, Lorenzana de Rivera, Ivette, additional, Lukashov, Vladimir, additional, Maayan, Shlomo, additional, Mayr, Luzia, additional, McCutchan, Francine, additional, Meda, Nicolas, additional, Menu, Elisabeth, additional, Mhalu, Fred, additional, Mloka, Doreen, additional, Mokili, John L, additional, Montes, Brigitte, additional, Mor, Orna, additional, Morgado, Mariza, additional, Mosha, Fausta, additional, Moussi, Awatef, additional, Mullins, James, additional, Najera, Rafael, additional, Nasr, Mejda, additional, Ndembi, Nicaise, additional, Neilson, Joel R, additional, Nerurkar, Vivek R, additional, Neuhann, Florian, additional, Nolte, Claudine, additional, Novitsky, Vlad, additional, Nyambi, Philippe, additional, Ofner, Marianna, additional, Paladin, Fem J, additional, Papa, Anna, additional, Pape, Jean, additional, Parkin, Neil, additional, Parry, Chris, additional, Peeters, Martine, additional, Pelletier, Alexandra, additional, Pérez-Álvarez, Lucía, additional, Pillay, Deenan, additional, Pinto, Angie, additional, Quang, Trinh Duy, additional, Rademeyer, Cecilia, additional, Raikanikoda, Filimone, additional, Rayfield, Mark A, additional, Reynes, Jean-Marc, additional, Rinke de Wit, Tobias, additional, Robbins, Kenneth E, additional, Rolland, Morgane, additional, Rousseau, Christine, additional, Salazar-Gonzales, Jesus, additional, Salem, Hanan, additional, Salminen, Mika, additional, Salomon, Horacio, additional, Sandstrom, Paul, additional, Santiago, Mario L, additional, Sarr, Abdoulaye D, additional, Schroeder, Bryan, additional, Segondy, Michel, additional, Selhorst, Philippe, additional, Sempala, Sylvester, additional, Servais, Jean, additional, Shaik, Ansari, additional, Shao, Yiming, additional, Slim, Amine, additional, Soares, Marcelo A, additional, Songok, Elijah, additional, Stewart, Debbie, additional, Stokes, Julie, additional, Subbarao, Shambavi, additional, Sutthent, Ruengpung, additional, Takehisa, Jun, additional, Tanuri, Amilcar, additional, Tee, Kok Keng, additional, Thapa, Kiran, additional, Thomson, Michael, additional, Tran, Tyna, additional, Urassa, Willy, additional, Ushijima, Hiroshi, additional, van de Perre, Philippe, additional, van der Groen, Guido, additional, van Laethem, Kristel, additional, van Oosterhout, Joep, additional, van Sighem, Ard, additional, van Wijngaerden, Eric, additional, Vandamme, Anne-Mieke, additional, Vercauteren, Jurgen, additional, Vidal, Nicole, additional, Wallace, Lesley, additional, Williamson, Carolyn, additional, Wolday, Dawit, additional, Xu, Jianqing, additional, Yang, Chunfu, additional, Zhang, Linqi, additional, and Zhang, Rong, additional

Published
2019
Full Text
View/download PDF

15. Detection of Immunoglobulin M and Immunoglobulin G Antibodies Against Orientia tsutsugamushi for Scrub Typhus Diagnosis and Serosurvey in Endemic Regions.

Author

Gupte, Mohan D., Gupte, Manish, Kamble, Suchit, Mane, Arati, Sane, Suvarna, Bondre, Vijay, Deshpande, Jagadish, Gadkari, Deepak, and Murhekar, Manoj V.

Subjects
IMMUNOGLOBULIN M, IMMUNOGLOBULIN G, TSUTSUGAMUSHI disease, CEREBROSPINAL fluid, IMMUNOGLOBULINS, DIAGNOSIS
Abstract

Objectives: To estimate the regional cutoff of optical density (OD) values for immunoglobulin M (IgM) antibodies against Orientia tsutsugamushi in serum and cerebrospinal fluid (CSF) for clinical diagnosis of scrub typhus and immunoglobulin G (IgG) antibodies in serum for sero-epidemiology in Gorakhpur, Uttar Pradesh, India. Methods: We used data from a serological investigation of acute encephalitis syndrome patients (n=407) during the 2016 outbreak in Gorakhpur, India to determine the cutoff for OD values for IgM antibodies, and from community-based serosurveys (n=1991) to estimate the cutoff for OD values for IgG antibodies. Results: We determined regionally relevant cutoff for OD values of 0.76 for IgM antibodies in serum and 0.22 in cerebrospinal fluid for scrub typhus diagnosis. For serosurveys, IgG antibody cutoff was 1.5. Conclusions: We have proposed locally relevant cutoffs for scrub typhus endemic regions, which may be useful for correctly classifying infected population. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

16. Rapid Disease Progression in Human Immunodeficiency Virus Type 1-Infected Seroconverters in India

Author

Mehendale, Sanjay M., primary, Bollinger, Robert C., additional, Kulkarni, Smita S., additional, Stallings, Rebecca Y., additional, Brookmeyer, Ronald S., additional, Kulkarni, Sangita V., additional, Divekar, Anand D., additional, Gangakhedkar, Raman R., additional, Joshi, Smita N., additional, Risbud, Arun R., additional, Thakar, Madhuri A., additional, Mahajan, Bharati A., additional, Kale, Varsha A., additional, Ghate, Manisha V., additional, Gadkari, Deepak A., additional, Quinn, Thomas C., additional, and Paranjape, Ramesh S., additional

Published
2002
Full Text
View/download PDF

20. RNA interference & inhibition of viruses.

Author

Gadkari DA

Subjects
Animals, Antiviral Agents pharmacology, Humans, Point Mutation, RNA, Small Interfering genetics, RNA, Small Interfering pharmacology, Temperature, Virus Diseases drug therapy, Virus Diseases virology, Virus Physiological Phenomena, Virus Replication drug effects, Viruses drug effects, RNA Interference, Viruses genetics
Published
2005

Catalog

Books, media, physical & digital resources
See catalog results